Trials / Terminated
TerminatedNCT03145909
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-176 for participants with advanced solid tumors likely to express Prolactin Receptor (PRLR). The study will consist of 2 cohorts: Dose Escalation and Expanded Recommended Phase 2 Dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-176 | Intravenous infusion |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2018-11-27
- Completion
- 2018-11-27
- First posted
- 2017-05-09
- Last updated
- 2018-11-29
Locations
11 sites across 4 countries: United States, Australia, Denmark, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03145909. Inclusion in this directory is not an endorsement.